PLEASANTON, Calif.--(BUSINESS WIRE)--HintMD, a leading cloud-based patient engagement and commerce platform for aesthetic practitioners, today announced that Mark Foley has been appointed chairman of the board of directors.
Considered an industry visionary, Mr. Foley most recently served as chairman, president and CEO of ZELTIQ* Aesthetics (ZLTQ). He brings to HintMD more than 25 years of healthcare operational and investment experience. Earlier this year, he led the sale of ZELTIQ to Allergan (AGN) for $2.5 billion.
“HintMD is honored to have Mark join as chairman of our board. As a leading ambassador of the aesthetic industry, there is no doubt that Mark’s appointment is a significant win for our team,” said Aubrey Rankin, co-founder and CEO of HintMD. “Mark brings valuable corporate governance, board oversight, as well as commercial and operational experience to our team. More important, he truly represents our values and is fully committed to HintMD’s mission in delivering technology-based engagement solutions for consumers, providers and leading aesthetic brands.”
Mr. Foley said, “I’m excited to join HintMD and believe that there is a huge unmet need that the company will be able to fill. Additionally, I’m impressed with the quality of the team and the progress made to date. I look forward to working closely with the HintMD organization to deliver value to our physician partners, their patients and our investors.”
Mr. Foley is the managing director of RWI Ventures, a venture capital firm focused on life sciences, networking, semiconductor and software investments. Previously, he was chairman, president and CEO of ZELTIQ Aesthetics, serving from 2012 through the company’s acquisition by Allergan. During his tenure, he led ZELTIQ’s growth from $68 million in annual revenue in 2012 to more than $350 million in 2016. Prior to ZELTIQ, Mr. Foley held a variety of senior operating roles in large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic) where he was the founder and CEO. He is a board member at Revance Therapeutics (RVNC) and Glaukos (GKOS) and also serves as chairman of ULab. Mr. Foley received a B.A. degree from the University of Notre Dame.
About HintMD
HintMD is a leading cloud-based patient engagement and commerce platform for aesthetic practitioners. Founded in 2014, the company partners with board certified physicians to create insight into gaps in patient care and offers personalized treatment plan subscription solutions to drive patient engagement, compliance and improved clinical outcomes. Its services result in significant compliance improvements, patient satisfaction and growing practice revenues and profitability. The company is based in Pleasanton, California, supporting the needs of the medical aesthetic industry consisting of more than 30,000 physician-owned practices. For more information, please visit www.hintmd.com.
